Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Aminu Yakubu, Nchangwi Syntia Munung, and Jantina De Vries, PhD
African cancer research is embedded in underresourced health care infrastructures, illuminating ethical questions about benefit sharing and governance.
AMA J Ethics. 2020;22(2):E156-163. doi:
10.1001/amajethics.2020.156.
Christopher W. Reynolds joins Ethics Talk to discuss his article, coauthored with Camilo Sánchez Meertens: “How Should Health Systems Help Clinicians Manage Bias Against Ex-combatants?”
Professor Leonard Rubenstein joins Ethics Talk to discuss his article, coauthored with Dr Rohini Haar: “What Does Ethics Demand of Health Care Practice in Conflict Zones?”